tbuckley/cabot-search huggingface dataset:
Putting the research into practice
Authors: P. Hay
Journal: BMJ (2003)

Bulimia nervosa occurs in about 1% of young women in Western countries. It is often chronic and adversely affects quality of life.1 The rate of diagnosis is very low, and community and primary care studies have shown that treatment is often delayed.2 3 An important contributing factor to this delay is the secrecy and shame around binge eating, self induced vomiting, and laxative misuse.4

Bulimia nervosa should be suspected in young and middle aged women who present with weight and shape concerns (whether they are normal or overweight)3 or with common comorbid conditions such as depression, anxiety, or substance …
SP0057 The course of systemic sclerosis (SSC): what can we learn from registries?
Authors: M. Matucci Cerinic
Journal: Annals of the Rheumatic Diseases (2018)

<h3></h3> SSc is a heterogeneuous connective tissue disease with an unpredictable course and a high mortality and morbidity. Although the identification of patients in early stages of disease is increasingly achievable thanks to the introduction of the new ACR/<sup><sup>EULAR 2013</sup></sup> classification criteria, the stratification of patients according to the risk of disease progression or of severity of disease is still an unmet need. Several potential predictive factors of disease evolution have been proposed over the years: SSc specific autoantibodies related to disease complications, serum biomarkers of internal organ involvement, age at diagnosis, sex, disease subset seem to have a prognostic value but unfortuntely all these may be present in different combinations making it difficult to identify how the disease will evolve. Data from registries of different countries confirm that the clinical presentation depends on several factors. Data from EUSTAR group data base indicate that a late age at onset (&gt;75 years) of SSc is associated with more aggressive disease as well as the male gender, that has a more severe phenotype and a worst prognosis than female, with an increased risk of occurrence of cardiovascular involvement. The analysis of geographic variations among different SSc presentations may suggest that eastern centres care for more severe SSc manifestations in Europe. Data from EUSTAR group reported also that the main causes of deaths in SSc are due to pulmonary fibrosis, pulmonary arterial hypertension (PAH) and heart involvement (mainly heart failure and arrhythmias). Independent risk factors for mortality and their seem to be proteinuria, the presence of PAH based on echocardiography, pulmonary, forced vital capacity below 80% of normal, dyspnoea above NYHA class II , reduction of dlco, patient age at onset of Raynaud's phenomenon and the modified Rodnan skin score. Interestingly, SSc patients show an increase risk of lung cancer (especially non small cell lung carcinoma) in association with interstitial lung disease and of esophageal or cardial adenocarcinoma. Data from the database of the German Network for Systemic Scleroderma support the concept that SSc-overlap syndromes should be regarded as a separate SSc subset, distinct from lcSSc and dcSSc, due to a different progression of the disease, that had an intermediate rate of disease progression in between lcSSc and dcSSc, different proportional distribution of specific autoantibodies, and of different organ involvement. Therefore, the use of registries is today of paramount importance to obtain significant data about several unmet needs in SSc. <h3>Disclosure of Interest</h3> None declared
Does Provider Experience Treating Patients (pts) with Myelodysplastic Syndromes (MDS) Explain Duration of Hypomethylating Agent (HMA) Therapy and Overall Survival (OS)? A Large Population-Based Analysis
Authors: Amer M. Zeidan, Xin Hu, Weiwei Zhu, Maximilian Stahl, Smith Giri, Scott F Huntington, Rong Wang, Nikolai A. Podoltsev, Steven D. Gore, Xiaomei Ma, Amy J. Davidoff
Journal: Blood (2018)
SAT0129 Trends in the incidence of cardiovascular diseases in patients with rheumatoid arthritis in spain: an observational cohort study of hospital discharges from 1999 to 2015 (TREND-AR STUDY)
Authors: C. MacíaVilla, R. Mazzucchelli, E. Perez Hernandez, J. Quirós, J. L. Morell Hita, N. Crespí, M. Peña, C. Barbadillo, M. Espinosa, H. Godoy, M. Fernandez Prada, M. Galindo, A. Garcia Vadillo, O. Guzon Illescas, A. Herranz, C. Martinez Prada, C. Morado Quiñoa, V. Villaverde
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Several changes have appeard in the last years in the management of Rheumatoid Arhritis (RA), and also a greater awareness about cardiovascular risk has emerged. However, the trend of CVDs in RA in Spain is unknown. <h3>Objectives</h3> To analyze the incidence and trend of hospital admissions for CVDs in patients with RA in Spain during the period between 1999 and 2015. <h3>Methods</h3> We performed an observational retrospective population study analyzing the spanish administrative database that includes a Minimun Basic Data Set (MBDS) of hospital admissions of patients with RA 1999-2015. We selected the MBDSs for CVDs, myocardial infarction (MI), ischemic heart disease (IHD), congestiveheart failure (CHF), cerebrovascular disease (CeVD) and aortic aneurysm (AA). Cases were identified by the presence in primary and secondary diagnosis of ICD9 codes. The population at risk was estimated through the population censuswith an estimated prevalence of RA of 0,5% (0,8% women, 0,2% men). Crude and adjusted rates were calculated, and the trend was analyzed using the Generalized Linear Model (GLM) with the year as the analysis variable. SPSS statistical package version 20 (SPSS Inc, Chicago, IL) was used. <h3>Results</h3> 338.343 RA hospital admissions were detected in the period, being 207.597 (61,3%) due to CVDs. table1 summarizes the data of the six subgroups of CVDs. <h3>Conclusions</h3> CVDs were the first cause of hospital admissions in Spain in RA patients during the period 1999-2015. Moreover, in that period there was an increasing incidence of hospital admissions due to CVDs in all the studied subgroups, being strikingly higher inmen after age-adjusted rates. An annual rate increase is estimated in all the different studied subgroups oscilating between 5 and 9% annual increasing. <h3>Disclosure of Interest:</h3> None declared
Challenges With Postoperative Cognitive Impairment Research
Authors: Rameela Chandrasekhar, E. Wesley Ely, Mayur B. Patel
Journal: JAMA Surgery (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal
Microvascular endothelial cells engulf myelin debris and promote macrophage recruitment and fibrosis after neural injury
Authors: Tian Zhou, Yiming Zheng, Li Sun, Smaranda Ruxandra Badea, Yuanhu Jin, Yang Liu, Alyssa J. Rolfe, Haitao Sun, Xi Wang, Zhijian Cheng, Zhaoshuai Huang, Na Zhao, Xin Sun, Jinhua Li, Jianqing Fan, Choogon Lee, Timothy L. Megraw, Wutian Wu, Guixue Wang, Yi Ren
Journal: Nature Neuroscience (2019)
AB0951 Ultrasonographic assessment of nail in psoriatic disease found a link between nail disorder and soft tissue swelling around the nail
Authors: T. Okano, K. Inui, Y. Yamada, K. Mandai, K. Mamoto, Y. Sugioka, T. Koike, H. Nakamura
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Although skin lesion is the most typical findings in patients with psoriasis (PsO), nail psoriasis is also one of the clinical manifestation. Moreover, nail disorders in PsO are known as a risk factor for psoriatic arthritis (PsA). However, pathological feature and the relationship with inflammation of the soft tissue around the nail is unknown.<sup>1–2</sup> <h3>Objectives</h3> The aim of this study was to compare the soft tissue thickness around the nail in patients with PsO, PsA and other rheumatic diseases by using ultrasonography. <h3>Methods</h3> Twenty-five PsO · 35 PsA · 23 rheumatoid arthritis (RA) · 28 ulcerative colitis (UC) and 13 Crohn's disease (CD) patients performed ultrasonographic assessment in nail were included in this analysis. Ultrasonographic examination was performed by using HI VISION Ascendus (Hitachi Medical Corporation, Japan) with a multifrequency linear transducer (18–6 MHz) and the grey scale (GS) and power Doppler (PD) findings were assessed. The distance between the proximal nail fold on the dorsal side of the nail matrix and the nail bed on the volar side of the nail matrix was measured by electric calliper <h3>Results</h3> The distance between the proximal nail fold and the nail bed was 2.58±0.56 mm in PsA and 2.55±0.58 mm in PsO patients (p=0.603). Among the 60 patients who combined PsO and PsA patients, 41 patients with nail psoriasis and 19 patients without nail psoriasis was compared. The distance was 2.68±0.62 mm in patients with nail psoriasis and 2.30±0.41 mm in without nail psoriasis (p&lt;0.001), which was also swelling compared with the RA, UC and CD group. <h3>Conclusions</h3> Soft tissue thickness around the nail in patients with PsO and PsA was compared with other rheumatic diseases by ultrasonographic assessment. In patients with PsO and PsA with nail psoriasis, soft tissue swelling around nail was observed. <h3>References</h3> [1] Sandobal C, Carbó E, Iribas J, et al. Ultrasound nail imaging on patients with psoriasis and psoriatic arthritis compared with rheumatoid arthritis and control subjects. J Clin Rheumatol. 2014;20:21–4. [2] Aydin SZ, Castillo-Gallego C, Ash ZR, et al. Ultrasonographic assessment of nail in psoriatic disease shows a link between onychopathy and distal interphalangeal joint extensor tendon enthesopathy. Dermatology. 2012;225:231–5. <h3>Acknowledgements</h3> We wish to thank Tomoko Nakatsuka for clinical assistant, Setsuko Takeda, Emi Yamashita and Yuko Yoshida for their special efforts as a sonographer and collecting data. <h3>Disclosure of Interest</h3> None declared
Abstract 15954: A Randomized Trial of the Effect of Antihypertensive Therapy at Low, Intermediate, and High Altitude: The INTERVENCION Study
Authors: Josefina Medina-Lezama, Offdan Narvaez Guerra, Karela Herrera Enriquez, Mardelangel Zapata Ponze De Leon, Angely Janeth Rondon Rodríguez, Sandra Perez Moscoso, Julio A Chirinos
Journal: Circulation (2016)

Background: Altitude above sea level has a major influence on cardiovascular function, but no data exist regarding the chronic effect of altitude on the response to antihypertensive therapy. Similarly, randomized trials assessing different pharmacologic agents for the treatment of hypertension among populations living at moderate or high altitude are lacking. Methods: We performed a prospective, randomized, multicenter clinical trial (clinicaltrials.gov NCT02373163) in which 146 subjects with untreated hypertension were enrolled at low altitude (LA,  3500 m), in a 1:2:2 ratio. At each altitude level, subjects were randomized in a 1:1:1 ratio to hydrochlorothiazide (25 mg/d), amlodipine (10 mg/d) or telmisartan (80 mg/d) for 28 days. At each altitude level, randomization was stratified by age group and gender to achieve an equal distribution across altitude levels The primary endpoint of the trial was the change in 24-hour systolic bl...
Abstract 19777: The Long Noncoding RNA Kcna2 AS Contributes to Ventricular Arrhythmias via Silencing Kcna2 in Rats With Congestive Heart Failure
Authors: Hao Wang, Qingqing Long, Liansheng Wang
Journal: Circulation (2017)

Introduction: Congestive heart failure (CHF) is a common cardiovascular disease that is often accompanied by ventricular arrhythmias. The decrease of the slow component of the delayed rectifier pot...
Determinants of Long-Term Outcome in Type 1/like Calreticulin-Mutated Myelofibrosis
Authors: Natasha Szuber, Terra L. Lasho, Christy Finke, Curtis A. Hanson, Rhett P. Ketterling, Animesh Pardanani, Naseema Gangat, Ayalew Tefferi
Journal: Blood (2018)
Th17 cell frequency is associated with low bone mass in primary sclerosing cholangitis
Authors: Tobias Schmidt, Dorothee Schwinge, Tim Rolvien, Anke Jeschke, Constantin Schmidt, Mona Neven, Sebastian Butscheidt, Marvin Kriz, Lilly Kunzmann, Haider Mussawy, Jan Hubert, Thelonius Hawellek, Wolfgang Rüther, Ralf Oheim, Florian Barvencik, Ansgar W. Lohse, Christoph Schramm, Thorsten Schinke, Michael Amling
Journal: Journal of Hepatology (2019)
The functional biology of peanut allergens and possible links to their allergenicity
Authors: Peggy Ozias‐Akins, Heimo Breiteneder
Journal: Allergy (2019)

Abstract Peanut is one of the most common food triggers of fatal anaphylaxis worldwide although peanut allergy affects only 1%‐2% of the general population. Peanuts are the source of highly potent allergenic proteins. It is emerging that the allergenicity of certain proteins is linked to their biological function. Peanut is an unusual crop in that it flowers aboveground but produces its seed‐containing pods underground. This so‐called geocarpic fruiting habit exposes pods and seeds during their development to soilborne pathogens and pests. Pest damage can also open routes of entry for opportunistic fungi such as Aspergillus . Although seed proteins have primary functions in nutrient reservoirs, lipid storage bodies, or the cytoskeleton, they have also evolved to act as part of the plant's defense system to enhance fitness and survival of the species. When interacting with pathogens or pests, these proteins modify and damage cells' membranes, interact with immune receptors, and modulate signaling pathways. Moreover, following exposure, the immune system of predisposed individuals reacts to these proteins with the production of specific IgE. This review explores the evolutionary biology of peanut and its seed proteins and highlights possible links between the proteins' biological function and their allergenicity.
SAT0102 Pristane-induced arthritis in dark agouti rat: a new animal model to study cardiovascular dysfunction in rheumatoid arthritis
Authors: M. Chouk, R. Bordy, J. Moretto, M. Tournier-Nappey, C. Prati, D. Wendling, P. Totoson, C. Demougeot
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Rheumatoid arthritis (RA) is characterised by an increased cardiovascular (CV) mortality. Animal models provide the opportunity to study CV features in RA, however, most used animal models develop a "monophasic" arthritis, making those models inappropriate for long-term studies on CV impairments. <h3>Objectives</h3> The aim of this study was to characterise vascular function and cardio-metabolic parameters in the "chronic" model of pristane-induced arthritis (PIA) in Dark Agouti (DA) rats. <h3>Methods</h3> 80 rats DA received an intradermal injection of 150 µL of pristane (PIA) or of saline solution (controls) at day 0. Arthritis score was daily followed. Acetylcholine (Ach) and sodium nitroprusside (SNP) -induced vasorelaxation were studied in macrovascular (aortic rings pre-contracted with serotonin) and in microvascular levels (mesenteric artery segments pre-contracted with phenylephrine) at day 28 (acute phase) and day 120 (chronic phase). Radiographic score, circulating markers of inflammation, lipid and glucose levels were also measured. <h3>Results</h3> PIA rats developed an acute arthritis phase from day 13 to day 50 followed by a remission phase, then by a chronic arthritis phase from day 70 to day 120. Radiographic score was higher in chronic than in acute phase in PIA (p&lt;0.001). Levels of IL-6, total cholesterol and triglycerides were higher in PIA than in controls at both phases (p&lt;0.001) whereas plasma myeloperoxidase activity and glycaemia were unchanged. Adiponectine levels were lower in PIA compared to controls in acute (p&lt;0.001) but not in chronic phase. Ach-induced vasorelaxation in macrovascular bed was significantly reduced in PIA compared to controls in acute (p&lt;0.05) but not in chronic phase. Furthermore, an altered Ach-induced vasorelaxation was shown in microvascular bed in PIA in chronic (p&lt;0.001) but not in acute phase. No altered SNP-induced vasorelaxation was observed between groups at both phases in both vascular beds. Endothelial function (EF) negatively correlated with arthritis score (p&lt;0.001), IL-6 (p&lt;0.05) and total cholesterol (p&lt;0.05) levels in macrovascular but not in microvascular bed. No correlation was found between EF and myeloperoxidase activity, adiponectin and triglycerides levels in both vascular beds. <h3>Conclusions</h3> PIA model shares several features of the CV alterations in RA: an endothelial dysfunction at the micro- and macrovascular level with independency of course among these vascular beds, a link between inflammation and macrovascular endothelial dysfunction, associated with low lipid levels. These data suggest that this model would be very useful for long-term pharmacological studies as well for deciphering the complex pathophysiology of increased CV risk in RA. <h3>Disclosure of Interest</h3> None declared
Abstract 13796: Safety of Subcutaneous Cenderitide Co-Therapy With LVAD Support: A Phase I, Placebo Controlled Cross-Over Study for Heart Failure
Authors: Tomoko Ichiki, John A Schirger, LuAnne J Koenig, Jacqueline R Wanek, Denise M Heublien, Christopher G Scott, Lyle D Joyce, Horng H Chen, Johh C Burnett
Journal: Circulation (2016)

Introduction: While left ventricular assist devise (LVAD) support improves the prognosis of end-stage heart failure (HF) patients, the long-term outcomes remains suboptimal. Improved outcomes may occur with organ protection including reverse myocardial remodeling. Cenderitide (CDNP) is a Mayo engineered designer natriuretic peptide (NP) that co-activates particulate guanylyl cyclase A and B receptors and functions via the second messenger cGMP. We reported a NP deficient state in the heart with LVAD support which lays the rationale for NP replacement therapy with Cenderitide which has cardiorenal protective actions in experimental HF. We sought to determine if Cenderitide co-therapy would be safe and activate cGMP in patients with LVAD support. Hypothesis: Acute single dose of subcutaneous (SQ) Cenderitide will be safe and activate cGMP in patients with LVAD support. Methods: Stable HF patients with LVAD support (Heartmate II, all males) were enrolled in a cross-over design comparing SQ placebo and low (Low-C, 5 ug/kg, n=8) or high dose (High-C, 10 ug/kg, n=8) Cenderitide (Capricor Therapeutics) administration. Vital signs, plasma C(D)NP, cGMP, Aldosterone (Aldo), and NT-proBNP levels were measured before or after drug administration over 24 hours. All parameters in Cenderitide group were adjusted by those in placebo. Results: Both Low-C and High-C group demonstrated significantly increased plasma C(D)NP and cGMP levels for 2 hours after drug injection and those in High-C group showed more prolonged and higher increases than Low-C group. Mean arterial pressure (MAP) in Low-C did not show any changes but in High-C group tended to be lower for 18 hours but this was not significant. Plasma Aldo and NT-proBNP levels in Low-C group did not show any change but those in High-C group tended to be lower after drug injection s similar to the change in MAP. No adverse events were observed in the study. Conclusions: SQ Cenderitide was successfully absorbed, activated cGMP and well tolerated in patients with LVAD support. High dose Cenderitide may have cardiac unloading effects suggested by decreases in NT-proBNP. Further clinical trial for efficacy is warranted to clarify cardiorenal protective effects of Cenderitide in the LVAD population to improve outcomes.
THU0187 Circulating autoantibodies as indicators to predict the clinical response to infliximab in rheumatoid arthritis
Authors: L. Lourido, C. Ruiz-Romero, F. Picchi, E. Pérez-Pampín, C. Regueiro, A. Mera-Varela, A. Gonzalez, K. Hambardzumyan, S. Saevarsdottir, P. Nilsson, F.J. Blanco
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Approximately a third of Rheumatoid Arthritis (RA) patients treated with tumour necrosis factor (TNF)-α inhibitors such as Infliximab (IFX) fail to respond. This has prompted a widespread interest in the finding of measures for predictors of response to TNFα inhibitors. <h3>Objectives</h3> To search for serum autoantibodies that aid to identify RA patients most likely to benefit from IFX. <h3>Methods</h3> We analysed serum of 170 biologic-naïve RA patients at baseline assigned to receive IFX plus methotrexate. The serum samples were distributed in 3 independent samples sets that were provided by 3 different sources: 1 discovery sample set (n=24) collected from Hospital Clínico Universitario of Santiago de Compostela (Spain) and 2 validation sample sets collected from Hospital Universitario de A Coruña (Spain), (n=61); and the Swedish Farmacotherapy (SWEFOT) trial (Sweden), (n=85). The European League Against Rheumatism (EULAR) criteria were used to assess the clinical response at six months of follow-up: good response (GR, n=60), moderate (MR, n=60) and non-response (NR, n=50). A suspension bead array platform built on protein fragments within Human Protein Atlas and selected from an initial screening using an array containing 42 000 antigens was employed to identify the IgG and IgA autoantibodies in the discovery sample set and validate the results within the 2 validation sets. Thresholds for autoantibodies were calculated by Receiver Operating Characteristics (ROC) curve analysis performed with SPSS 24. <h3>Results</h3> Our data revealed a more prevalent IgG reactivity and higher IgG autoantibody levels against the antigen Centromere Protein F (CENPF) in GR when compared with NR, showing an overall reactivity of 31% <i>vs</i> 0%, 45% vs. 26% and 17% vs 4% in the three sample sets analysed respectively. The area under the ROC curve was 0,649 [p-value=0.049; IC 95% (0.510–0.789)]. CENP-F is a proliferation-associated and cell cycle-dependent centromere autoantigen that might be involved in the increased or abnormal cell proliferation that occurs during RA process. Interestingly, our results also showed that IgA autoantibodies levels toward the antigen Solute Carrier family 39 member 2 (SLC39A2), a zinc transporter protein, were decreased in GR when compared with MR in the discovery sample set and this trend was significantly validated (p=0.018) in the SWEFOT cohort. The area under the ROC curve was 0,681 [p-value=0,019; IC95% (0,543–0,818)]. <h3>Conclusions</h3> We have identified two autoantibodies in RA that associate with IFX response. Our findings could potentially be useful to guide the treatment decisions for IFX and lead to further studies focusing on the role of the autoantibodies against CENPF and SLC39A2 within RA. <h3>Disclosure of Interest</h3> None declared